|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Targeted therapy for hepatocellular carcinoma显示文摘The last 3 years have seen the emergence of promising targeted therapies for the treatment of hepatocellular carcinoma(HCC).Sorafenib has been the mainstay of treatment for a decade and newer modalities were ineffective and did not confer any increased therapeutic benefit until the introduction of lenvatinib which was approved based on its non-inferiority to sorafenib.The subsequent success of regorafenib in HCC patients who progress on sorafenib treatment heralded a new era of second-line treatment and was quickly followed by ramucirumab,cabozantinib,and the most influential,immune checkpoint inhibitors(ICIs).Over the same period combination therapies,including anti-angiogenesis agents with ICIs,dual ICIs and targeted agents in conjunction with surgery or other loco-regional therapies,have been extensively investigated and have shown promise and provided the basis for exciting clinical trials.Work continues to develop additional novel therapeutic agents which could potentially augment the presently available options and understand the underlying mechanisms responsible for drug resistance,with the goal of improving the survival of patients with HCC. | Ao Huang Xin-Rong Yang Wen-Yuan Chung Ashley R.Dennison Jian Zhou | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 7 |
| 2 | Laparoscopic pancreatic surgery: a review of present results and future prospects显示文摘 | Omer S.Al‐Taan James A.Stephenson ChristopherBriggs CristinaPollard Matthew S.Metcalfe Ashley R.Dennison | 2010 | HPB2010，，4： | 1 |
| 3 | Laparoscopic pancreatic surgery: a review of present results and future prospects显示文摘 | Omer S.Al‐Taan James A.Stephenson ChristopherBriggs CristinaPollard Matthew S.Metcalfe Ashley R.Dennison | 2010 | HPB2010，，4： | 1 |
| 4 | Segmental nature of the porcine liver and its potential as a model for experimental partial hepatectomy显示文摘 | F. G.Court S. A.Wemyss‐Holden C. P.Morrison B. D.Teague P. E.Laws J.Kew A. R.Dennison G. J.Maddern | 2003 | Br J Surg2003，，4： | 1 |
| 5 | Assessment of long-term graft function following total pancreatectomy and autologous islet transplantation:the Leicester experience显示文摘Background:Total pancreatectomy and islet autotransplantation(TPIAT)is a recognised treatment for chronic pancreatitis(CP)with the potential to mitigate or prevent pancreatogenic diabetes.We present our 10-year follow-up of TPIAT patients.Methods:The University Hospitals of Leicester performed 60 TPIAT procedures from September 1994 to May 2011.Seventeen patients completed their 10-year assessment and were grouped using the modified Auto-Igls criteria;good response,n=5(insulin-independent for first 5 years post-TPIAT);partial response,n=6(insulin requirements<20 iU/day post-TPIAT)and poor response,n=6(insulin requirements≥20 iU/day post-TPIAT).C-peptide,haemoglobin A1c(HbA1c)and oral glucose tolerance test(OGTT)were undertaken preoperatively(baseline),then at 3,6 months and then yearly for 10 years.Data was analysed using analysis of variance(ANOVA).Results:Median C-peptide levels were significantly higher,120 minutes following OGTT,in the“good response”compared to“partial”and“poor”groups(two-way ANOVA test,P<0.0001).All groups demonstrated preservation of C-peptide release.HbA1c levels were significantly lower in the“good response”compared to“partial”and“poor”groups(two-way ANOVA test,P<0.0003 and P<0.0001).Median fasting glucose levels at 30 and 120 min following OGTT,were significantly lower in the“good response”compared to“partial”and“poor”groups(two-way ANOVA test,P<0.0001 and P<0.0001).Conclusions:TPIAT preserves long-term islet graft functions in 10-year follow up.Even in patients in the poor response group,there is evidence of C-peptide release(>0.5 ng/mL)after OGTT stimulation potentially preventing long-term diabetes-related complications. | Cristina APollard Wen Yuan Chung Giuseppe Garcea Ashley R.Dennison | 2023 | Hepatobiliary Surgery and Nutrition2023，12，5： | 0 |
| 6 | Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro显示文摘Objective:Pancreatic cancer(PC)is an aggressive cancer with ineffective treatment.Inhibition of stearoyl-CoA desaturase 1(SCD1)suppresses cancer proliferation and might act as a novel chemotherapy supplement,but this has not been investigated in PC.Here,the effects of SCD1 inhibitor CAY10566 supplemented with gemcitabine treatment(gemcitabine+CAY10566)on PC cell viability,apoptosis,phenotype,fatty acid content,platelet-derived growth factor release,and cell size were investigated.Methods:Human PC cell line(PANC-1)was treated with SCD1 inhibitor CAY10566 with or without gemcitabine.Cell viability was assayed using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide and apoptosis and phenotype were determined using flow cytometry.Fatty acid content and platelet-derived growth factor release were measured by enzyme-linked immunosorbent assay.Cell size was determined using scanning electron microscopy.Results:Half-maximal inhibitory concentration of gemcitabine or CAY10566 significantly reduced PANC-1 viability compared to gemcitabine alone(P<0.0001).No significant differences in the phenotype of phosphatidylserine,tissue factor or basigin expression were detected at therapeutic doses(P>0.05).Apoptosis was significantly increased following incubation with CAY10566(P<0.05).Fatty acid content of cells was significantly higher following gemcitabine treatment compared to CAY10566 alone or gemcitabine+CAY10566(P<0.05).Platelet-derived growth factor released by gemcitabine-treated cells was significantly increased compared to 142 nM CAY10566 alone or gemcitabine+CAY10566(P<0.01).CAY10566 did not affect the size of isolated tumor cells but gemcitabine+CAY10566 significantly increased the size compared to the control(P<0.05).Cell viability decreased significantly after the treatment with gemcitabine+CAY10566 compared with CAY10566 alone(P<0.05)and gemcitabine alone(P<0.01).However,when cycles of chemotherapy were mimicked and treatment was removed,the number of cell viability was significantly reduced(P<0.05).Conclusion:This study suggests that CAY10566 may be a suitable supplement for gemcitabine chemotherapy for PC. | Amon B.Hackney Wen Y.Chung John Isherwood Ashley R.Dennison Naomi Martin | 2021 | Journal of Pancreatology2021，4，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员